LP 2307: Will begin in the fourth quarter a Phase I/II trial in 18 patients with late Stage III or IV disease and life expectancy of less than a year. Dosing an

LIDAK Pharmaceuticals (LDAKA), La Jolla, Calif. Product: LP 2307, Large Multivalent Immunogen technology, in which antigens isolated from tumor are attached to cell-sized microspheres to stimulate tum...